Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

August 31, 2009

Conditions

Dengue

Interventions

BIOLOGICAL

rDEN4delta30-4995

Live attenuated rDEN4delta30-4995 vaccine (one of three doses)

BIOLOGICAL

Placebo

Placebo for rDEN4delta30-4995

Trial Locations (1)

Vanderbilt University School of Medicine, Nashville

All Listed Sponsors

collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00322946 - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults | Biotech Hunter | Biotech Hunter